EVOLUS, INC. Contract with Customer, Receivable, Credit Loss Expense (Reversal)
EVOLUS, INC. (EOLS) reported Contract with Customer, Receivable, Credit Loss Expense (Reversal) of $2.38 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal · last filed 2020-10-29
- EVOLUS, INC. contract with customer, receivable, credit loss expense (reversal) for the quarter ending 2020-09-30 was $2.38M, a 58.57% decline year-over-year.
- EVOLUS, INC. contract with customer, receivable, credit loss expense (reversal) for the quarter ending 2019-09-30 was $5.74M.
| Period end | Contract with Customer, Receivable, Credit Loss Expense (Reversal) 3 month | Contract with Customer, Receivable, Credit Loss Expense (Reversal) 9 month |
|---|---|---|
| 2020-09-30 | $2.38M 10-Q · filed 2020-10-29 | $12.61M 10-Q · filed 2020-10-29 |
| 2019-09-30 | $5.74M 10-Q · filed 2020-10-29 | $6.67M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |